Ken Griffin Vor Biopharma Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.7 - $1.1 $5,460 - $8,580	7,800 Added 520.0%	9,300 $6,000
Q2 2024 Aug 14, 2024	SELL	$1.0 - $2.2 $300 - $660	-300 Reduced 16.67%	1,500 $1,000
Q1 2024 May 15, 2024	SELL	$1.8 - $2.85 $2,880 - $4,560	-1,600 Reduced 47.06%	1,800 $4,000
Q4 2023 Feb 14, 2024	SELL	$1.66 - $2.63 $4,648 - $7,364	-2,800 Reduced 45.16%	3,400 $7,000
Q3 2023 Nov 14, 2023	BUY	$2.1 - $3.35 $8,190 - $13,065	3,900 Added 169.57%	6,200 $13,000
Q2 2023 Aug 14, 2023	SELL	$3.09 - $5.33 $48,513 - $83,681	-15,700 Reduced 87.22%	2,300 $7,000
Q1 2023 May 15, 2023	SELL	$4.68 - $6.96 $27,144 - $40,368	-5,800 Reduced 24.37%	18,000 $96,000
Q4 2022 Feb 14, 2023	BUY	$3.77 - $7.43 $89,726 - $176,834	23,800 New	23,800 $158,000

41.2M

9.3K

100

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $33.1M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.